Tubutecan Platform: Technology-enabled Payload Solutions Targeting Topoisomerase-I

Time: 10:00 am
day: Day One


  • Understand how Tubulis’ P5-conjugation technology enabled rapid generation of stably linked, hydrophilic DAR8 ADCs from native antibodies
  • Topoisomerase-I-inhibitors have become a promising payload class for ADCs in solid tumors. Tubutecans are a novel linker-payload platform for ADCs enabling the efficient and steady delivery of the TOPO-I-targeting payloads to the malignant cells
  • Evaluate how the implementation of an in vitro screen for on-target/off-tumor effects aids in designing the optimal combination of linker-payload and DAR matched with target properties